Effect of compound Haishe capsule combined with rivastigmine on serum thyroid hormone, inflammatory factor and coagulation function in patients with Alzheimer's disease
10.3760/cma.j.issn.1008-6706.2019.18.007
- VernacularTitle: 复方海蛇胶囊联合卡巴拉汀对阿尔茨海默病患者疗效及其血清甲状腺激素、炎性因子和凝血功能影响研究
- Author:
Lingshan QIU
1
;
Ou XU
2
;
Chunyan WANG
3
Author Information
1. Department of Gerontology, the Seventh People's Hospital of Hangzhou, Hangzhou, Zhejiang 310013, China
2. Department of Prevention, the Seventh People's Hospital of Hangzhou, Hangzhou, Zhejiang 310013, China
3. Outpatient Department, the Seventh People's Hospital of Hangzhou, Hangzhou, Zhejiang 310013, China
- Publication Type:Journal Article
- Keywords:
Alzheimer disease;
Dementia;
Hydrophidae;
Rivastigmine;
Thyroxine;
Inflammation mediators
- From:
Chinese Journal of Primary Medicine and Pharmacy
2019;26(18):2204-2208
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effects of compound Haishe capsule combined with rivastigmine capsule on serum thyroid hormone, inflammatory factors and coagulation function in patients with Alzheimer's disease(AD).
Methods:From January 2016 to January 2018, 74 patients with AD in the Seventh People's Hospital of Hangzhou were randomly divided into control group and observation group according to the digital table, with 37 cases in each group.The control group was treated with rivastigmine capsule, while the observation group was treated with compound Haishe capsule on the basis of the control group.The two groups were treated for 6 months.The therapeutic effects of the two groups were compared.The changes of BEHAVE-AD and ADAS-Cog scores, thyroid hormones, inflammatory factors and coagulation function were compared before and after treatment.
Results:The total effective rate of the observation group was 94.59%(35/37), which was higher than 72.97%(27/37) of the control group(u=6.366, P<0.05). After treatment, the scores of BEHAVE-AD and ADAS-Cog in the observation group were (4.87±0.64)points, (14.28±1.82)points, respectively, which were lower than those in the control group[(8.91±1.07)points, (18.93±1.25)points](t=19.710, 12.811, all P<0.05). After treatment, the level of FT4 in the observation group was (13.09±0.71)pmol/L, which was higher than (12.30±0.52)pmol/L in the control group (t=5.460, P<0.05). After treatment, the levels of CRP and IL-6 in the observation group were (2.13±0.38)mg/L, (31.32±5.64)ng/L, respectively, which were lower than those in the control group[(3.47±0.61)mg/L, (58.93±12.15)ng/L](t=11.342, 12.538, all P<0.05). After treatment, the levels of D-dimer and Fib in the observation group were (519.82±10.29)μg/L, (3.21±0.32)ng/L, respectively, which were lower than those in the control group[(552.31±8.31)μg/L, (4.12±0.49)ng/L](t=14.942, 9.458, all P<0.05).
Conclusion:Compound Haishe capsule combined with rivastigmine capsule is effective in the treatment of AD, and can improve thyroid hormone and coagulation function, and reduce the level of inflammatory factors.
